HOXA9 and glioblastoma: Together, our findings indicate that the HOXA9 transcriptome in GBM cells may be reverted by several drugs with potential anticancer effects, particularly those interfering with PI3K signaling, HDAC and HSP90 functions, which may be clinically valuable to revert HOXA9-driven transcriptomic signatures.